Trial Disruptions Due To COVID-19? Adaptive Bayesian Approaches Reveal Promising Possibilities

A number of trials have been disrupted by the onslaught of the COVID-19 pandemic. A Cytel panel discussion reveals the strategic advantage of using Bayesian methods to resolve a number of trial challenges ranging from small sample sizes, flexible designs, missing data, and unpredictable recruitment. Here leading biostatisticians and former regulators discuss the opportunities these adaptive Bayesian methods offer.